Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440126 · ClinicalTrials.gov registry record
Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk
A clinical trial of Multiple Sclerosis, sponsored by Rocky Mountain MS Research Group.
- Completed
- Registry status
- 196
- Enrollment target
- 1
- Study location
NCT02440126: Completed study of Multiple Sclerosis, sponsored by Rocky Mountain MS Research Group.
NCT02440126 is a study of Multiple Sclerosis that has completed, run by Rocky Mountain MS Research Group. The registered enrollment target is 196 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02440126, a study of Multiple Sclerosis, has completed, sponsored by Rocky Mountain MS Research Group.
- COMPLETED
- Registry status
- 196 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to develop an improved understanding of the long term pharmacokinetics and pharmacodynamics of natalizumab with both standard dosing and extended dosing, and collect additional samples to explore cell-based biomarkers of natalizumab treatment and PML risk.
Primary Outcome
Changes in natalizumab concentration (ug/ml) will be collected and compared to similar infusion cycle lengths collected previously in investigator-initiated trials at this site.
Conditions Studied
Study Locations (1)
Utah
- Rocky Mountain MS Research Group - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2014-10 |
| Est. Completion | 2020-07 |
What the finished NCT02440126 record still lists
NCT02440126 is an observational study that tracks outcomes without assigning an intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT02440126 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02440126 about?
NCT02440126 is a clinical study titled "Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk". The purpose of the study is to develop an improved understanding of the long term pharmacokinetics and pharmacodynamics of natalizumab with both standard dosing and extended dosing, and collect additional samples to explore cell-based biomarkers of natalizumab treatment and PML risk.
What is the current status of trial NCT02440126?
This trial is currently completed. The enrollment target is 196 participants. The study started on 2014-10. Estimated completion is 2020-07.
What conditions does trial NCT02440126 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT02440126?
This trial is sponsored by Rocky Mountain MS Research Group, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02440126 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02440126's enrollment target sits among peer trials
196 80th of 315 higher than 236 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia